Clinical Trial Update: Study Of CP-751,871 In Patients With Ewing's Sarcoma Family Of Tumors [Phase 1, Phase 2]

View source ↗

Summary

Pfizer-sponsored Phase 1/2 study of CP-751,871 in patients with Ewing's sarcoma family of tumors completed and posted results in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ewing Sarcoma
• Ewing Sarcoma Family of Tumors

Drugs mentioned

• CP-751,871 (dalotuzumab)

Snippet

Sponsor: Pfizer | Conditions: Ewing's Sarcoma Family of Tumors | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2014-02-28